Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection

References

• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
   PubMed Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on chronic lymphocytic leukemia. N Engl J Med. 1998; 338(21):1506–1514.
   PubMed Web of Science ®Google Scholar
• CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999; 91(10):861–868.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Byrd JC, Call TG, et al. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 2006; 145(6):435–447.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al.; RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib alone or in combination with rituximab produces superior progression free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): results of alliance North American Intergroup Study A041202. Blood. 2018;132(Suppl 1):6.
   Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(1):43–56.
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–1200.
   PubMed Web of Science ®Google Scholar
• Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO Phase III study. J Clin Oncol. 2019;37(4):269–277.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291.
   PubMed Web of Science ®Google Scholar
• Langerbeins P, Zhang C, Robrecht S, et al. The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia. Blood. 2022;139(2):177–187.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–234.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer Am Cancer Soc. 1981;48(1):198–206.
   Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V-H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247–3254.
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85(6):1580–1589.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III trial E2997. J Clin Oncol. 2007;25(7):799–804.
   PubMed Web of Science ®Google Scholar
• International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6):779–790.
   PubMed Web of Science ®Google Scholar
• da Cunha-Bang C, Christiansen I, Niemann CU. The CLL-IPI applied in a population-based cohort. Blood. 2016; 128(17):2181–2183.
   PubMed Web of Science ®Google Scholar
• Gentile M, Shanafelt TD, Mauro FR, et al. Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. Eur J Haematol. 2018;101(5):703–706.
   Web of Science ®Google Scholar
• Soumerai JD, Ni A, Xing G, et al. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in Idelalisib phase-3 trials. Leuk Lymphoma. 2019;60(6):1438–1446.
   PubMed Web of Science ®Google Scholar
• Brander DM, Rhodes J, Pagel JM, et al. Applicability of the chronic lymphocytic leukemia (CLL)-IPI on patients treated with front-line ibrutinib in the real world: the case for new prognostic models. Blood. 2017;130(Suppl 1):1719.
   Google Scholar
• Kreuzberger N, Damen JA, Trivella M, et al. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2020;7:CD012022.
   PubMedGoogle Scholar
• Rigolin GM, Cavallari M, Quaglia FM, et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood. 2017;129(26):3495–3498.
   PubMed Web of Science ®Google Scholar
• Ahn IE, Tian X, Ipe D, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2021;39(6):576–585.
   PubMed Web of Science ®Google Scholar
• Brieghel C, Aarup K, Torp MH, et al. Clinical outcomes in patients with Multi-Hit TP53 chronic lymphocytic leukemia treated with ibrutinib. Clin Cancer Res. 2021;27(16):4531–4538.
   PubMed Web of Science ®Google Scholar
• Soumerai JD, Ni A, Alperovich A, et al. Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma. Leuk Lymphoma. 2020;61(12):2939–2946.
   PubMed Web of Science ®Google Scholar
• Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–215.
   PubMed Web of Science ®Google Scholar
• Herling CD, Coombes KR, Benner A, et al. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncol. 2019;20(11):1576–1586.
   PubMed Web of Science ®Google Scholar
• Mato AR, Nabhan C, Barr PM, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199–2205.
   PubMed Web of Science ®Google Scholar
• Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009; 170(2):244–256.
   PubMed Web of Science ®Google Scholar
• Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007; 26(11):2389–2430.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94(446):496–509.
   Web of Science ®Google Scholar
• Fine JP, Jiang H, Chappell R. On semi-competing risks data. Biometrika. 2001; 88(4):907–919.
   Web of Science ®Google Scholar
• Kendall MG. A new measure of rank correlation. Biometrika. 1938;30(1–2):81–93.
   Google Scholar
• Soumerai JD, Ni A, Darif M, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019;6(7):e366–e374.
   PubMed Web of Science ®Google Scholar
• Molica S, Giannarelli D, Visentin A, et al. Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model. Am J Hematol. 2022; 97(5):E176–E180.
   PubMed Web of Science ®Google Scholar
• Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996;22(5–6):439–447.
   PubMed Web of Science ®Google Scholar
• Lee L, Wang L, Crump M. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin’s lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol. 2011; 22(6):1392–1403.
   PubMed Web of Science ®Google Scholar
• Sylvan SE, Asklid A, Johansson H, et al. First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica. 2019;104(4):797–804.
   PubMed Web of Science ®Google Scholar
• Prentice RL. Surrogate endpoints in clinical-trials – definition and operational criteria. Stat Med. 1989; 8(4):431–440.
   PubMed Web of Science ®Google Scholar
• Mato A, Nabhan C, Kay NE, et al. Prognostic testing patterns and outcomes of chronic lymphocytic leukemia patients stratified by fluorescence in situ hybridization/cytogenetics: a real-world clinical experience in the connect CLL registry. Clin Lymphoma Myeloma Leuk. 2018;18(2):114–124.e2.
   PubMed Web of Science ®Google Scholar
• Schlette EJ, Admirand J, Wierda W, et al. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma. 2009;50(10):1597–1605.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24(3):437–443.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Brown J, Abramson JS, et al. NCCN guidelines(R) insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2022. J Natl Compr Canc Netw. 2022;20(6):622–634.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink AM, Bahlo J, et al.; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–942.
   PubMed Web of Science ®Google Scholar